Alfresa HoldingsALFRY 75 3-Year ROIIC % is 16.65 as of Mar. 2026, which is 304% above its 10-year median of 4.12. GuruFocus rates ALFRY with a GF Score™ of 75/100 and a GF Value™ of $16.25 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 112 Medical Distribution companies, Alfresa Holdings ranks better than 81.25% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Alfresa Holdings's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 16.65%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Alfresa Holdings's 3-Year ROIIC % or its related term are showing as below:
ALFRY's 3-Year ROIIC % is ranked better than 81.25% of 112
companies
in the Medical Distribution industry
Industry Median: 2.145
vs ALFRY: 16.65
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Alfresa Holdings 3-Year ROIIC % Related Terms
Alfresa Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Alfresa Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Alfresa Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Alfresa Holdings (ALFRY) has a 3-Year ROIIC % of 16.65 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alfresa Holdings and its competitors. This is 304% above median its historical median of 4.12. According to the industry distribution chart, Alfresa Holdings ranks #21 out of 112 companies in the Medical Distribution industry, placing it in the top 18.7%.
Is Alfresa Holdings' 3-Year ROIIC % too high?
Alfresa Holdings' current 3-Year ROIIC % of 16.65 is 304% above median its 10-year median of 4.12. The Medical Distribution industry median 3-Year ROIIC % is 2.15. Alfresa Holdings' value of 16.65 is 676.2% above this industry median. Based on the distribution chart, Alfresa Holdings ranks #21 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Alfresa Holdings has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' 3-Year ROIIC % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #21 out of 112 companies for 3-Year ROIIC %. This places Alfresa Holdings in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 2.15. Alfresa Holdings' value of 16.65 is 676.2% above this benchmark. While the company's 10-year median is 4.12 vs. the industry median of 2.15, Alfresa Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.15, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current 3-Year ROIIC % of 16.65 is 676.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alfresa Holdings and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current 3-Year ROIIC % is 16.65, which is 304% above median its own 10-year median of 4.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ALFRY) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.25, compared to a current price of $13.80 — trading 15.1% below its estimated fair value. The current 3-Year ROIIC % is 16.65, which is 304% above median its 10-year median of 4.12 and 676.2% above the Medical Distribution industry median of 2.15. Alfresa Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Alfresa Holdings (ALFRY), the current 3-Year ROIIC % is 16.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ALFRY) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be undervalued.
The current stock price of $13.80 is trading 15.1% below its estimated GF Value™ of $16.25.
GuruFocus considers Alfresa Holdings to be Modestly Undervalued.
Key valuation signals for ALFRY:
3-Year ROIIC %: 16.65 (304% above median its 10-year median of 4.12)
GF Value™: $16.25 vs. price of $13.80 (15.1% below fair value)
Industry Position: 676.2% above the Medical Distribution median (#21 of 112)
No single metric tells the full story. See the ALFRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
75GF Score
Get the complete analysis for ALFRY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALFRY has been successfully added to your 
